全崴生技股份有限公司

Our International Partners

*
*

CID Group, China and Taiwan

The CID Group was founded in 1998 to carry out the mission of “Integrating Global Resources to Create Synergistic Businesses”. Today, CID has become one of the fastest growing Asia-headquartered private equity firms. CID is one of the major shareholders of Transwell and continuously provides financial advice and supports to Transwell.

*

Easywell Biomedicals, Taiwan

Easywell Biomedicals (TWOTC: 1799) is the parent company of Transwell Biotech. Easywell has several subsidiaries locating in China, Taiwan and the U.S. to provide a wide spectrum of medical products, ranging from medical devices, pharmaceutical products to regenerative medicine products.

*

Elanix Inc., Switzerland

Headquartered in Nyon, Switzerland, Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. Transwell is the exclusive licensee of using Elanix’s progenitor cells in treating wounds.

*

Industrial Technology Research Institute (ITRI), Taiwan

Founded in 1973, Industrial Technology Research Institute (ITRI) is one of the world’s leading technology R&D institutions aiming to deliver a better future for society. ITRI contributes a lot in Transwell’s product development by providing services of GMP-manufacturing as well as various QC and CMC tests.

*

TAHO Pharmaceuticals, Ltd., Taiwan

TAHO is a specialty pharmaceutical company. It designs and develops new drug with its transdermal or transmucosal delivery platform to bring niche markets to existing compounds. Transwell and TAHO are working closely to design and develop a transdermal patch for Parkinson's.

*

Nippi Inc., Japan

Nippi Inc. is a company primarily engaged in the manufacturing and sales of collagen products, gelatin products, collagen cosmetics, leather products and health foods. Nippi’s clinical grade products play important roles in Transwell’s product development. Both parties are working closely to make new use of Nippi’s product in regenerative medicine.